Corporate Overview
about : corporate overview
Novel Oncolytic Virus-Based Platform Technology to Transform the Detection and Treatment of Cancer.
Genelux Corporation is a privately-held, clinical stage biopharmaceutical company with a mission to change the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic virus-based technology platform and a deep pipeline of products for cancer detection and therapy.
GL-ONC1, the company’s lead oncology product candidate, is an attenuated vaccinia virus (Lister strain) that results in dramatic regression and elimination of a wide range of solid tumors in animals without damaging healthy tissues or organs. GL-ONC1 encodes Green Fluorescent Protein (GFP) to enable highly selective imaging of tumors and metastases as an aid in the diagnosis and staging of cancer. Currently under evaluation in human clinical trials in United Kingdom, GL-ONC1 is proving well-tolerated with minimal side effects and showing early signs of anti-tumor activity.
The company’s R&D efforts have yielded a wide variety of new applications for its platform and imaging technologies, including:
- Targeted viruses armed for cancer therapy and diagnosis
- Customized viral vectors encoding selected or "Your Favorite Genes" (YFG’s) for treatment of specific tumor types
- Highly specific deep tissue imaging capabilities (PET and MRI)
- Veterinary oncology applications
Genelux is headquartered in California, with additional operations in Germany.